Moderate Or Severe Hepatic Impairment clinical trials

Explore recruiting moderate or severe hepatic impairment clinical trials.

Recruiting moderate or severe hepatic impairment studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Moderate Or Severe Hepatic Impairment trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Camizestrant in Post-menopausal Female Subjects

Bulgaria, Slovakia

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Study to Evaluate CC-486 in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Cancer Participants

Spain, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1, Open-label, Pharmacokinetic Study of TVB-2640 in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Function.

Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Single-Dose Pharmacokinetic Study of Lepodisiran in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function

Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function

Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Study of Oral Tazemetostat in Subjects With Moderate and Severe Liver Impairment With Advanced solid tumors or hematological malignancies

Belgium, Poland, Slovakia, France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Moderate Or Severe Hepatic Impairment trials by city

Moderate Or Severe Hepatic Impairment in Toronto Moderate Or Severe Hepatic Impairment in Vancouver Moderate Or Severe Hepatic Impairment in Montreal Moderate Or Severe Hepatic Impairment in Calgary Moderate Or Severe Hepatic Impairment in Edmonton Moderate Or Severe Hepatic Impairment in Ottawa Moderate Or Severe Hepatic Impairment in Winnipeg Moderate Or Severe Hepatic Impairment in Quebec City Moderate Or Severe Hepatic Impairment in Hamilton Moderate Or Severe Hepatic Impairment in Kitchener Moderate Or Severe Hepatic Impairment in London Moderate Or Severe Hepatic Impairment in Halifax Moderate Or Severe Hepatic Impairment in New York Moderate Or Severe Hepatic Impairment in Los Angeles Moderate Or Severe Hepatic Impairment in Chicago Moderate Or Severe Hepatic Impairment in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease